Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

PURPOSE: Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapse...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Younes, Anas, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Ramchandren, Radhakrishnan, Bartlett, Nancy L., Cheson, Bruce D., de Vos, Sven, Forero-Torres, Andres, Moskowitz, Craig H., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Kennedy, Dana A., Sievers, Eric L., Chen, Robert
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2012
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646316/
https://ncbi.nlm.nih.gov/pubmed/22454421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.38.0410
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items